{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964155,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00296-017-3690-9","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T02:38:25Z","timestamp":1488422305000},"page":"1207-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review"],"prefix":"10.1007","volume":"37","author":[{"given":"Shen-ju","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-you","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"issue":"3","key":"3690_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrd3669","volume":"11","author":"K Redlich","year":"2012","unstructured":"Redlich K, Smolen JS (2012) Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11(3):234\u2013250. doi:10.1038\/nrd3669","journal-title":"Nat Rev Drug Discov"},{"issue":"9746","key":"3690_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. The Lancet 376(9746):1094\u20131108. doi:10.1016\/S0140-6736(10)60826-4","journal-title":"The Lancet"},{"issue":"3","key":"3690_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molmed.2016.01.005","volume":"22","author":"L Semerano","year":"2016","unstructured":"Semerano L, Minichiello E, Bessis N, Boissier MC (2016) Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol Med 22(3):214\u2013229. doi:10.1016\/j.molmed.2016.01.005","journal-title":"Trends Mol Med"},{"issue":"23","key":"3690_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219. doi:10.1056\/NEJMra1004965","journal-title":"N Engl J Med"},{"issue":"1","key":"3690_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/bmb\/lds022","volume":"103","author":"E Lawson","year":"2012","unstructured":"Lawson E, Walker-Bone K (2012) The changing spectrum of rheumatic disease in HIV infection. Br Med Bull 103(1):203\u2013221. doi:10.1093\/bmb\/lds022","journal-title":"Br Med Bull"},{"issue":"5","key":"3690_CR6","first-page":"799","volume":"26","author":"Q Yao","year":"2008","unstructured":"Yao Q, Frank M, Glynn M, Altman RD (2008) Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 26(5):799\u2013806","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3690_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.autrev.2008.07.009","volume":"8","author":"M Galeazzi","year":"2008","unstructured":"Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C et al (2008) Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 8(2):100\u2013103. doi:10.1016\/j.autrev.2008.07.009","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3690_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","volume":"50","author":"HT Idriss","year":"2000","unstructured":"Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50(3):184\u2013195. doi:10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","journal-title":"Microsc Res Tech"},{"key":"3690_CR9","doi-asserted-by":"publisher","first-page":"484378","DOI":"10.1155\/2013\/484378","volume":"2013","author":"A Kumar","year":"2013","unstructured":"Kumar A, Abbas W, Herbein G (2013) TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm 2013:484378. doi:10.1155\/2013\/484378","journal-title":"Mediators Inflamm"},{"issue":"2","key":"3690_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.intimp.2015.04.051","volume":"27","author":"K Chaabo","year":"2015","unstructured":"Chaabo K, Kirkham B (2015) Rheumatoid Arthritis-Anti-TNF. Int Immunopharmacol 27(2):180\u2013184. doi:10.1016\/j.intimp.2015.04.051","journal-title":"Int Immunopharmacol"},{"issue":"29","key":"3690_CR11","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2174\/138161211798157658","volume":"17","author":"J Geiler","year":"2011","unstructured":"Geiler J, Buch M, McDermott MF (2011) Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 17(29):3141\u20133154","journal-title":"Curr Pharm Des"},{"issue":"2","key":"3690_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/01.rhu.0000260411.75599.39","volume":"13","author":"PP Kaur","year":"2007","unstructured":"Kaur PP, Chan VC, Berney SN (2007) Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 13(2):79\u201380. doi:10.1097\/01.rhu.0000260411.75599.39","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"3690_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/ard.2007.081513","volume":"67","author":"EJ Cepeda","year":"2008","unstructured":"Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008) The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67(5):710\u2013712. doi:10.1136\/ard.2007.081513","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3690_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1128\/CVI.00081-13","volume":"20","author":"P De Nardo","year":"2013","unstructured":"De Nardo P, Bellagamba R, Corpolongo A, Gentilotti E, Taglietti F, Rosati S et al (2013) Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report. Clin Vaccine Immunol 20(5):761\u2013764. doi:10.1128\/CVI.00081-13","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"3690_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253\u2013259. doi:10.1056\/NEJM199901283400401","journal-title":"N Engl J Med"},{"issue":"3","key":"3690_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00296-008-0681-x","volume":"29","author":"D Hu","year":"2009","unstructured":"Hu D, Bao C, Chen S, Gu J, Li Z, Sun L et al (2009) A comparison study of a recombinant tumor necrosis factor receptor: Fc fusion protein (rhTNFR: Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatol Int 29(3):297\u2013303. doi:10.1007\/s00296-008-0681-x","journal-title":"Rheumatol Int"},{"issue":"4","key":"3690_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jbspin.2013.01.002","volume":"80","author":"H Almoallim","year":"2013","unstructured":"Almoallim H, Jali I, Wali G (2013) Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia. Joint Bone Spine 80(4):426\u2013428. doi:10.1016\/j.jbspin.2013.01.002","journal-title":"Joint Bone Spine"},{"issue":"3","key":"3690_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4103\/0378-6323.110807","volume":"79","author":"V Di Lernia","year":"2013","unstructured":"Di Lernia V, Zoboli G, Ficarelli E (2013) Long-term management of HIV\/hepatitis C virus associated psoriasis with etanercept. Indian J Dermatol Venereol Leprol 79(3):444. (PubMed: 23619459)","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1 suppl","key":"3690_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0300060515593250","volume":"44","author":"C De Simone","year":"2016","unstructured":"De Simone C, Perino F, Caldarola G, D\u2019Agostino M, Peris K (2016) Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. J Int Med Res 44(1 suppl):67\u201371. (PubMed: 27683143)","journal-title":"J Int Med Res"},{"issue":"17","key":"3690_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medcli.2008.11.007","volume":"133","author":"T Cobo Ib\u00e1\u00f1ez","year":"2009","unstructured":"Cobo Ib\u00e1\u00f1ez T, Zamora F, Herranz P, Steiner M (2009) Anti-tumour necrosis factor treatment in HIV-positive patients with psoriatic arthritis. Med Cl\u00edn 133 (17):682\u2013683. (PubMed: 19243791)","journal-title":"Med Cl\u00edn"},{"issue":"3","key":"3690_CR21","first-page":"437","volume":"12","author":"J Gonzalez-Nicolas","year":"2001","unstructured":"Gonzalez-Nicolas J, Resino S, Jimenez JL, Alvarez S, Fresno M, Munoz-Fernandez MA (2001) Tumor necrosis factor-alpha and nitric oxide in vertically HIV-1-infected children: implications for pathogenesis. Eur Cytokine Netw 12(3):437\u2013444","journal-title":"Eur Cytokine Netw"},{"issue":"3 Pt 1","key":"3690_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0190-9622(97)70160-9","volume":"37","author":"L Tourne","year":"1997","unstructured":"Tourne L, Durez P, Van Vooren JP, Farber CM, Liesnard C, Heenen M et al (1997) Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol 37(3 Pt 1):501\u2013502","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3690_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","volume":"29","author":"NI Wada","year":"2015","unstructured":"Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S et al (2015) The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 29(4):463\u2013471. doi:10.1097\/QAD.0000000000000545","journal-title":"AIDS"},{"issue":"7","key":"3690_CR24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1073\/pnas.86.7.2336","volume":"86","author":"L Osborn","year":"1989","unstructured":"Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 86(7):2336\u20132340","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3690_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","volume":"18","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M et al (2004) A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18(2):257\u2013264","journal-title":"AIDS"},{"issue":"9","key":"3690_CR26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/088922202760019365","volume":"18","author":"BE Sha","year":"2002","unstructured":"Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R et al (2002) Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retrovir 18(9):661\u2013665. doi:10.1089\/088922202760019365","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"3690_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/infdis\/174.1.63","volume":"174","author":"RE Walker","year":"1996","unstructured":"Walker RE, Spooner KM, Kelly G, McCloskey RV, Woody JN, Falloon J et al (1996) Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 174(1):63\u201368","journal-title":"J Infect Dis"},{"issue":"4","key":"3690_CR28","first-page":"29","volume":"2","author":"JJ Emer","year":"2009","unstructured":"Emer JJ (2009) Is there a potential role for anti-tumor necrosis factor therapy in patients with human immunodeficiency virus? J Clin Aesthet Dermatol 2(4):29\u201335","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"3690_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-4632.2005.02642.x","volume":"45","author":"PT Ting","year":"2006","unstructured":"Ting PT, Koo JY (2006) Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 45(6):689\u2013692. doi:10.1111\/j.1365-4632.2005.02642.x","journal-title":"Int J Dermatol"},{"issue":"1","key":"3690_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","volume":"31","author":"MJ Shale","year":"2010","unstructured":"Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S (2010) Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 31(1):20\u201334. doi:10.1111\/j.1365-2036.2009.04112.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3690_CR31","first-page":"35","volume":"74","author":"S Ehlers","year":"2005","unstructured":"Ehlers S (2005) Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 74:35\u201339","journal-title":"J Rheumatol Suppl"},{"key":"3690_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","volume":"5","author":"T Ali","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS (2013) Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 5:79\u201399. doi:10.2147\/DHPS.S28801","journal-title":"Drug Healthc Patient Saf"},{"issue":"11","key":"3690_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2(11):602\u2013610. doi:10.1038\/ncprheum0336","journal-title":"Nat Clin Pract Rheumatol"},{"key":"3690_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12879-016-1389-2","volume":"16","author":"T Adizie","year":"2016","unstructured":"Adizie T, Moots RJ, Hodkinson B, French N, Adebajo AO (2016) Inflammatory arthritis in HIV positive patients: a practical guide. BMC Infect Dis 16:100. doi:10.1186\/s12879-016-1389-2","journal-title":"BMC Infect Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-017-3690-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:56:29Z","timestamp":1744160189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-017-3690-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3690-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]},"assertion":[{"value":"7 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}